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The Spectrum of Mesenchymal Tumors of the Skin
Cutaneous tumours of mesenchymal origin are relatively uncommon tumors, originating from non-epithelial skin structures and 
characterized by clinico-pathological heterogeneity.  Being classified histologically according to the mature tissue they resemble, 
these heterogeneous mesenchymal neoplasms show a broad range of differentiation and form the largest group of skin tumors.  The 
aim of the study was to analyze the incidence patterns and clinical peculiarities of cutaneous mesenchymal tumours according to the 
histologic type.  Research trials were conducted in the Institute of Oncology of the Republic of Moldova and included 1121 patients 
with cutaneous tumors of mesenchymal origin, surgically treated in the period 2004-2008, including 1036 (92.4%) benign tumors 
and 85 (7.6%) malignant tumors.  The most frequent benign tumors were hemangioma (52.4%) and dermatofibroma (33.7%).  Kaposi 
sarcoma was the most common form of cutaneous malignant mesenchymal tumors, accounting for 43.53% of cases. 41.18% of skin 
tumors of mesenchymal origin were reprezented by dermatofibrosarcoma protuberans, which is a locally aggressive tumor with a high 
recurrence rate and little metastatic potential.  This study demonstrated variation by age, sex and anatomic location in patients with 
cutaneous sarcomas according to the histologic type.
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Introduction
Cutaneous tumours of mesenchymal origin are a het-
erogeneous group of uncommon tumors, originating from 
non-epithelial skin structures.  Malignant mesenchymal 
tumors, called sarcomas, are far outnumbered by carcinomas, 
melanoma and benign mesenchymal neoplasms of skin and 
subcutis.  These heterogeneous mesenchymal neoplasms show 
a broad range of differentiation and are classified histologically 
according to the mature tissue they resemble, such as smooth 
muscle (leiomyosarcoma), endothelium (angiosarcoma), or 
fibroblast (eg. dermatofibrosarcoma protuberans) [3].  Benign 
mesenchymal tumors show an incidence of 3.000/1 million 
people and therefore are about a hundred times more frequent 
than malignant mesenchymal tumors (incidence of 30/1 
million).  Cutaneous soft tissue sarcomas represent < 1% of 
malignant tumors, and little is known regarding their etiology 
or incidence patterns.  Their behaviour varies from indolent 
to very aggressive, with consequent variation in survival, 
according to histological type, grade, and sometimes genetic 
constitution, but the overall 5 year survival is about 65-75%.
Although most tumors arise spontaneously, some risk fac-
tors have been identified.  Recent reports have linked specific 
genetic, immunodeficiency, irradiation, and environmental 
factors as well as viral infection with the development of mes-
enchymal cutaneous and noncutaneous tumors.  The most re-
cent World Health Organization (WHO) classification of soft 
tissue sarcomas takes into account type-specific cytogenetic 
and molecular findings in the classification [3].  Some tumors 
also arise in scars.  It is  known that the human herpes virus 8 
plays a role in the development of Kaposi sarcoma [1,5].  Other 
risk factors include chronic lymphedema, which increases the 
incidence of soft tissue sarcomas.  Angiosarcoma complicating 
longstanding lymphoedema especially after radical mastec-
tomy might also be due to local immunosuppression [10].  An 
association between exposure to herbicides, including dioxin, 
and sarcomagenesis is controversial and remains unproven. 
Sarcomas can arise in the field of prior therapeutic irradiation. 
Following irradiation for carcinoma of the breast, low-grade 
cutaneous angiosarcomas were noticed after an interval as 
short as 18 months [8].  Benign and malignant tumours 
present as usually painless masses, with varying growth rate. 
Cutaneous lesions form a plaque or elevated nodule that can 
ulcerate when malignant.
In general, sarcomas in skin or subcutis can be considered 
part of the group of soft tissue sarcomas and have a more 
favourable outcome than those located beneath deep fascia. 
The recent WHO classification of Tumours of Soft Tissue [3] 
recognizes three behavioural categories:
1. Benign tumours.  These rarely recur locally, and those 
that recur do so in a non-destructive fashion and are usually 
cured by local excision.  Exceptionally rarely, an otherwise 
(and histologically typical) benign tumour, such as cutaneous 
fibrous histiocytoma, can metastasize.
2. Intermediate tumours are those that are locally aggres-
sive and/or very occasionally metastasizing, such as dermato-
fibrosarcoma protuberans.  Rarely-metastasizing tumours are 
generally dermal or subcutaneous tumours which have a low 
(1-2%) but definite risk of metastasis, most often to regional 
lymph nodes but occasionally to lung.  Examples are recorded 
for plexiform fibrohistiocytic tumour and angiomatoid fibrous 
histiocytoma.
3. Malignant tumours infiltrate and recur locally and have 
an appreciable risk of metastasis (exceeding 20%).
Histologically, malignant soft tissue neoplasms are cha-
racterized by nuclear pleomorphism, mitotic activity includ-
ing abnormal forms, necrosis and vascular invasion.  Some 
benign tumours, however, can show one or more of these 
features.  Examples include nuclear atypia in cutaneous pleo-
morphic fibroma and atypical benign fibrous histiocytoma 
(which can also display necrosis), and frequent mitoses in 
nodular fasciitis.
Grading of tumors is an attempt to predict clinical behaviour 
based on histological variables.  It should be done on material 
from a primary untreated neoplasm, though change (increase) 
of grade can be noted in recurrent or metastatic tumor.  Of the 
grading systems that have been developed, those of the French 
Federation of Cancer Centers Sarcoma Group and the National 
Cancer Institute (both of which are 3-grade systems) are now the 
Спектр мезенхимальных опухолей кожи
Мезенхимальные опухоли кожи встречаются редко и возникают из неэпителиальных, мягкотканных компонентов 
кожи, характеризующиеся клинико-морфологической гетерогенностью.  Они составляют разнообразную группу опухолей 
кожи, согласно морфологической структуре.  Данное исследование имело цель определить эпидемиологические и клинико-
морфологические особенности опухолей кожи в зависимости от гистологического типа.  В работу было включено 1121 пациентов 
с мезенхимальными опухолями кожи, оперированных в Онкологическом Институте в течение 2004–2008 гг.  Из них, 1036 (92,4%) с 
доброкачественными, 85 (7,6%) с злокачественными опухолями.  Согласно исследованию, наиболее частыми доброкачественными 
опухолями являются дерматофиброма (33,7%) и гемангиома (52,4%).  Злокачественные мезенхимальные опухоли представлены 
саркомой Капоши (43,53%).  Выбухающая дерматофибросаркома, которая имеет медленный рост, локально агрессивное течение 
и склонность к рецидивам, встречается в 41,18% случаев кожных злокачественных мезенхимальных опухолей.  По данным 
исследования существуют вариации по возрасту, полу и анатомической локализации у больных с саркомой кожи в зависимости 
от гистологического типа опухоли.
Ключевые слова: мезенхимальные опухоли кожи, саркома Капоши, выбухающая дерматофибросаркома.
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most commonly used [2,3].  Briefly, tumors are given a score of 
1, 2 or 3 depending on the degree of differentiation; 1, 2 or 3 for 
number of mitoses per 10 hpf (< 10, 11 - 20, or > 20); and 0-2 
for amount of necrosis (0, < 50%, > 50%).  A total score count of 
2 or 3 is classified as grade 1, a score count of 4 or 5 as 2, and a 
score of 6, 7 or 8 as grade 3.
The staging of sarcomas is based on tumor grade, size, 
and location.  A widely used staging system for soft tissue 
sarcomas is that of the International Union against Cancer 
(UICC) (TNM system) and American Joint Commission 
on Cancer (AJCC).  Unlike many other tumours, staging of 
sarcomas includes histological grading as well as tumour size 
and depth from surface, regional lymph node involvement and 
distant metastasis.  Cutaneous sarcomas have a lower risk of 
metastasis than those located deeper; indeed histologically 
malignant leiomyosarcomas confined to skin are essentially 
non-metastasizing tumours.
Although some studies have reported the overall epidemi-
ology of soft tissue sarcomas, to our knowledge, no previous 
study has focused on the population-based epidemiology of 
cutaneous sarcomas in the Republic of Moldova.
The aim of the study
To conduct a comprehensive analysis of cutaneous tu-
mours of mesenchymal origin, including incidence rates and 
diagnostical peculiarities according to patient demographic 
characteristics and histologic type using the most recent cri-
teria of the WHO classification.
Material and methods
Research trials were conducted in the Institute of Oncology 
of the Republic of Moldova and included 1121 surgically trea-
ted patients with cutaneous benign and malignant tumors of 
mesenchymal origin in the period 2004-2008.  The diagnosis 
was confirmed by histologic examination of slides in all of 
the cases (100%).
The main part of the cases was represented by benign 
tumors (92.4%) and only 7.6% - by malignant tumors.  The 
most frequent benign tumors were hemangioma (52.4%) and 
dermatofibroma (33.7%) (tab. 1). The other cutaneous benign 
tumors constitued 13.9%.
In the current study, we investigated the epidemiology of 
soft tissue sarcomas that originated in the skin above the fascia 
Table 1
Cutaneous benign tumours of mesenchymal origin diagnosed during 2004 to 2008 by histologic type (number of cases)
Histologic type 2004 2005 2006 2007 2008 Total 
Dermatofibroma 70 51 73 84 71 349
Fibroma 8 6 3 4 15 36
Angiofibroma 1 2 5 1 9
Lipoma 1 3 1 2 5 12
Fibrolipoma 5 8 2 4 19
Leiomyoma 1 1 1 3
Angioleiomyoma 1 2 1 4
Capillary hemangioma 39 36 57 58 91 281
Cavernous hemangioma 35 43 34 31 38 181
Capillary-cavernous hemangioma 12 17 13 20 19 81
Neurofibroma 4 11 10 3 10 38
Neurilemmoma 3 3
Neurinoma (shwannoma) 1 1 1 5 4 12
Limfocytoma 1 1 2
Xantoma 3 3
Fibroxantoma 1 1
Juvenile xanthogranuloma 1 1
Abrikosov's tumor 1 1
Total 171 176 202 218 269 1036
Table 2
Cutaneous malignant tumours of mesenchymal origin diagnosed during 2004 to 2008 by histologic type and sex
Histologic type ICDO-3 Code(s)
Men Women All
No. of cases % No. of cases % No. of cases %
Kaposi sarcoma 9140 24 28.24 13 15.29 37 43.53
Dermatofibrosarcoma protuberans 8832,8833 25 29.41 10 11.76 35 41.18
Leiomyosarcoma 8890-8896 1 1.18 1 1.18 2 2.35
Angiosarcoma 9120,9130,9170 2 2.35 3 3.53 5 5.88
Malignant fibrous histiocytoma 8830 3 3.53 1 1.18 4 4.71
Malignant hemangioendothelioma 9130 1 1.18 1 1.18 2 2.35
Total cutaneous sarcomas 56 65.88 29 34.12 85 100
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rather than soft tissue sarcomas that arose from the subcu-
taneous or deeper connective tissue or from specific organs. 
The incidence data were evaluated for cutaneous soft tissue 
sarcomas diagnosed from 2004 through 2008 among residents 
of the Republic of Moldova.  Primary site and histologic type 
for each malignancy were coded according to the third edition 
of the International Classification of Diseases for Oncology 
(ICDO-3) [4].  We categorized individual 4-digit histology 
codes into major histologic groups according to the criteria 
specified in the latest 2002 WHO classification of soft tissue 
tumors [3].  The specific morphology codes that were used 
are shown in tab. 2.
Results and disscusion
In total, 85 cases of cutaneous malignant tumours of me-
senchymal origin were diagnosed from 2004 through 2008. 
The number of cases and percent distribution of these tumors 
according to histologic type are shown in tab. 2.
Kaposi sarcoma (KS) was the most common form of cu-
taneous soft tissue sarcomas, accounting for 43.53% of cases. 
The number of KS cases worldwide in 2002 was estimated at 
approximately 65,000 [9]. There are 4 main types of KS: classic 
KS, which typically occurs among elderly Mediterranean men 
or Ashkenazi Jews; human immunodeficiency virus (HIV)-
associated KS; endemic KS, which presents in individuals of 
Central African countries; and transplantation-related KS 
[6].  Although classic KS had been reported for over a century 
before the acquired immunodeficiency syndrome (AIDS) epi-
demic, it was rare, and its etiology was unknown [1, 6].  With 
the increase in KS cases, all 4 types of KS have been associated 
with human herpes virus 8 (HHV-8) [1, 6].  Regardless of the 
type of KS, the most common site is the skin.
Other major cutaneous soft tissue sarcoma constitued der-
matofibrosarcoma protuberans (DFSP) (41.18%).  The annual 
incidence of DFSP is reported as 3 cases per million, popula-
tion from a population-based cancer registry from 1982-2002 
in France [7].  DFSP is a very slowly growing tumor.  It may 
start as a small asymptomatic papule, which is likely ignored. 
The tumor may gradually enlarge into a lumpy nodule, or it 
may evolve into an atrophic or sclerotic plaque.  Because of 
the slow progression, the diagnosis is often delayed. DFSP 
is characterized by its aggressive local invasion.  The tumor 
invades local tissue by extending tentaclelike projections 
underneath healthy skin rendering complete removal of the 
tumor very difficult. Incomplete removal of these neoplastic 
cells results in a high local recurrence rate.  Despite the local 
invasiveness, DFSP rarely metastasizes.  The risk for devel-
opment of metastatic disease is only 5%, including 1% with 
regional lymph node metastasis and 4% with distant metas-
tasis.  Regional lymph node involvement represents a sign of 
poor prognosis; most patients die within 2 years.  The lungs 
are the most common site of distant metastasis that occurs via 
hematogenous spread.  Usually, metastatic disease is preceded 
by multiple local recurrences.
Together, these 2 histologic types (KS and DFSP) repre-
sented 84.71% of all cases.  Excluding Kaposi sarcoma and der-
matofibrosarcoma protuberans, the percentage distribution of 
the remaining cases of cutaneous sarcomas was: angiosarcoma 
– 5.88%, malignant fibrous histiocytoma – 4.71%, leiomyosar-
coma - 2.35% and malignant hemangioendothelioma – 2.35%. 
Kaposi sarcoma, as well as dermatofibrosarcoma protuberans, 
was most common among men.  The rate ratio of men to 
women was 1.85 for KS and 2.50 for DFSP.
Cutaneous soft tissue sarcomas differed in terms of 
anatomic distribution (tab. 3).  Head and neck was the most 
common site for dermatofibrosarcoma protuberans (28.57%) 
than for other malignant tumors, although DFSP occurred 
predominantly on the trunk (40.0%) and only 17.14% arose 
on upper extremity and 14.29% - on lower extremity.  Almost 
half (48.65%) of Kaposi sarcoma lesions arose on the lower 
Table 3
Cutaneous malignant tumours of mesenchymal origin diagnosed during 2004 to 2008  
by histologic type and anatomic location
Histologic type Total no. of cases
Head and neck Trunk Upper extremity Lower extremity Multisite
No. of 
cases %
No. of 
cases %
No. of 
cases %
No. of 
cases %
No. of 
cases %
Kaposi sarcoma 37 1 2.70 0 0 4 10.81 18 48.65 14 37.84
Dermatofibrosarcoma protuberans 35 10 28.57 14 40.0 6 17.14 5 14.29 0 0
Others 13 2 15.38 3 23.08 2 15.38 6 46.15 0 0
Table 4
Age and sex distribution of patients with cutaneous malignant tumours  
of mesenchymal origin by histologic type (number of cases)
Histologic type
less than 30 31-40 41-50 51-60 61-70 71-80 81 and over
M W M W M W M W M W M W M W
Kaposi sarcoma 2 4 1 6 4 7 2 3 2 2 4
DFSP 2 1 1 2 6 3 7 2 4 3 4
Others 3 1 1 1 1 1 1 2 2
Note: M-men, W-women.
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extremities and 37.84% occurred at multiple or overlapping 
cutaneous sites.  Other cutaneous sarcomas, including leio-
myosarcoma, angiosarcoma, malignant fibrous histiocytoma, 
malignant hemangioendothelioma were relatively proportio-
nate in their anatomic distribution.
We observed that Kaposi sarcoma occurred more fre-
quently among men than among women.  Kaposi sarcoma 
increased with age, peaked in the 60s, and subsequently 
declined.  Age-specific KS rates were bimodal, with rates 
elevated in middle adulthood and at oldest ages for women.
The current study reported that DFSP occurred most 
commonly during the fifth and sixth decades of life especially 
among men, whereas the incidence among women rose more 
modestly after age of 40. The rates for DFSP were higher 
among men than women during the middle adult years.
The bimodal distribution also was evident among patients 
with other types of cutaneous sarcomas. The first peak was 
highest at early ages for men, then the rates were constant 
across the middle age groups for both men and women and 
slightly increased in the 70s (tab. 4).
Conclusions
Benign mesenchymal tumors of the skin are much more 
frequent than their malignant counterparts. Cutaneous soft 
tissue sarcomas are relatively rare, but they can occur in almost 
any anatomic site.  Most cutaneous soft tissue sarcomas arise, 
de novo without an apparent causative factor.  Clinical signs 
are painless nodes of a xanthomatous aspect and rapid growth. 
Early diagnosis is crucial for the prognosis.  The etiology of 
most malignant mesenchymal tumors of the skin is unknown. 
Genetic, immunodeficiency and environmental factors, as well 
as viral infections, have been described as associated risk fac-
tors.  Gene-gene and gene-environment interactions also may 
contribute to cutaneous soft tissue sarcomas susceptibility.  In 
this study we analyzed the incidence patterns of cutaneous 
benign and malignant tumours of mesenchymal origin, and 
observed distinctive differences among the various histologic 
types and primary sites.  Although we had a good sample size 
in some instances, it was not large enough to allow for suf-
ficient power to estimate rates by stratification.  Other limita-
tions include lack of complete data for some patients and of 
a centralized pathology review of tumors.  The strengths of 
this study are the unbiased ascertainment and assessment of 
cases of some rare tumors and the fact that it is the first study 
focused on the epidemiology of cutaneous sarcomas in the 
Republic of Moldova.
In conclusion, this study has demonstrated that there is 
variation in cutaneous soft tissue sarcomas incidence patterns 
over time and by age, sex, and histologic type, supporting the 
notion that these tumors represent distinct clinical entities, 
likely because of genetic factors and environmental exposures. 
More than three-quarters of malignant tumours of mesen-
chymal origin in skin are represented by Kaposi sarcoma 
(KS) and dermatofibrosarcoma protuberans (DFSP).  Both 
KS and DFSP rates were highest among men and the age-
specific patterns varied by type.  Because sarcomas are rela-
tively uncommon and yet comprise a wide variety of different 
entities, evaluation by oncology teams who have expertise in 
the field is recommended. Further investigations using large 
populations and molecular tools are warranted to elucidate 
the etiology of the diverse spectrum of cutaneous tumors of 
mesenchymal origin.
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